BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/7/2021 8:39:45 AM | Browse: 431 | Download: 807
 |
Received |
|
2021-01-29 11:06 |
|
Peer-Review Started |
|
2021-01-29 11:14 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-02-28 20:40 |
|
Revised |
|
2021-03-29 09:51 |
|
Second Decision |
|
2021-05-20 06:58 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-05-20 10:58 |
|
Articles in Press |
|
2021-05-20 10:58 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-06-07 17:09 |
|
Typeset the Manuscript |
|
2021-06-23 04:49 |
|
Publish the Manuscript Online |
|
2021-07-07 08:39 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Editorial |
| Article Title |
COVID-19: Considerations about immune-suppression and biologicals at the time of SARS-CoV-2 pandemic
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Giulia Costanzo, William Cordeddu, Luchino Chessa, Stefano Del Giacco and Davide Firinu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Davide Firinu, MD, PhD, Assistant Professor, Doctor, Doctor, Research Fellow, Department of Medical Sciences and Public Health, University of Cagliari, Asse Didattico “E1” Medicina, Cittadella Universitaria, Monserrato 09042, Cagliari, Italy. davide.firinu@unica.it |
| Key Words |
COVID-19; Immune-mediated diseases; Biological drugs; Targeted therapies; Cytokine storm; Immunosuppressive drugs |
| Core Tip |
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has changed health systems worldwide and the current approach to patients affected by chronic diseases such as immune-mediated disorders. To apply personalized medicine, knowledge of the impact of SARS-CoV-2 during the course of immune-mediated diseases and particularly among patients treated with biologicals, together with the results of novel coronavirus disease 2019 treatment strategies targeting the virus and the host immune response, will help us to best manage our patients during this pandemic. |
| Publish Date |
2021-07-07 08:39 |
| Citation |
Costanzo G, Cordeddu W, Chessa L, Del Giacco S, Firinu D. COVID-19: Considerations about immune-suppression and biologicals at the time of SARS-CoV-2 pandemic. World J Clin Cases 2021; 9(20): 5352-5357 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i20/5352.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i20.5352 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
